CA3093706A1 - Jak inhibitors - Google Patents

Jak inhibitors Download PDF

Info

Publication number
CA3093706A1
CA3093706A1 CA3093706A CA3093706A CA3093706A1 CA 3093706 A1 CA3093706 A1 CA 3093706A1 CA 3093706 A CA3093706 A CA 3093706A CA 3093706 A CA3093706 A CA 3093706A CA 3093706 A1 CA3093706 A1 CA 3093706A1
Authority
CA
Canada
Prior art keywords
methyl
pyrimidin
pyrrolo
amino
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3093706A
Other languages
English (en)
French (fr)
Inventor
Xibin Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3093706A1 publication Critical patent/CA3093706A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3093706A 2018-03-21 2019-03-18 Jak inhibitors Pending CA3093706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646167P 2018-03-21 2018-03-21
US62/646,167 2018-03-21
PCT/US2019/022657 WO2019182924A1 (en) 2018-03-21 2019-03-18 Jak inhibitors

Publications (1)

Publication Number Publication Date
CA3093706A1 true CA3093706A1 (en) 2019-09-26

Family

ID=67986579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3093706A Pending CA3093706A1 (en) 2018-03-21 2019-03-18 Jak inhibitors

Country Status (7)

Country Link
US (1) US11365188B2 (https=)
EP (1) EP3768272B1 (https=)
JP (1) JP7462951B2 (https=)
CN (1) CN111936144B (https=)
AU (1) AU2019237991B2 (https=)
CA (1) CA3093706A1 (https=)
WO (1) WO2019182924A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509463B2 (en) 2019-01-30 2025-12-30 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102032934B1 (ko) * 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP3180344B1 (en) * 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
EP3248980B1 (en) 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
WO2018169700A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509463B2 (en) 2019-01-30 2025-12-30 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor

Also Published As

Publication number Publication date
CN111936144A (zh) 2020-11-13
WO2019182924A1 (en) 2019-09-26
EP3768272A4 (en) 2021-08-11
US20210053943A1 (en) 2021-02-25
EP3768272B1 (en) 2025-07-30
EP3768272A1 (en) 2021-01-27
JP7462951B2 (ja) 2024-04-08
AU2019237991B2 (en) 2025-01-02
JP2021518379A (ja) 2021-08-02
CN111936144B (zh) 2023-12-22
AU2019237991A1 (en) 2020-10-15
US11365188B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
CN115590854B (zh) 哒嗪基噻唑甲酰胺类化合物
CA3093706A1 (en) Jak inhibitors
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
CA2828478C (en) Serine/threonine kinase inhibitors
AU2018392616B2 (en) Quinazolinones as PARP14 inhibitors
TWI543981B (zh) 作為ｃ－ｋｉｔ激酶抑制劑之化合物及組合物
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
US12435079B2 (en) Bruton's tyrosine kinase inhibitors
CN116528864A (zh) 杂芳基甲酰胺化合物
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
CA3082156A1 (en) Heterocyclic compound as a protein kinase inhibitor
CN116813647B (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CA3055602A1 (en) Bruton's tyrosine kinase inhibitors
JP2022534510A (ja) ヤヌスキナーゼ１の阻害のための新規化合物
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
CN102656172B (zh) 8-氧代二氢嘌呤衍生物
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
JP7335972B2 (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
JP2018529724A (ja) キナーゼ阻害剤としての縮合ピリジン誘導体
JP7851393B2 (ja) 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤
RU2833828C2 (ru) Новые соединения для ингибирования янус-киназы 1
JP2024527623A (ja) 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
JP2026509913A (ja) Ｈｓｐ９０阻害剤としてのアデニン誘導体
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240305

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250304

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250530

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723